Overview
Indications
Abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Boxed Warning
FDA Black Box Warning
Hypersensitivity Reactions Warnings and Precautions (5.1) [see] Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir, a component of abacavir and lamivudine. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensit
Contraindications
When this intervention should not be used
Abacavir and lamivudine tablets are contraindicated in patients: Warnings and Precautions (5.1) [see] who have the HLA-B*5701 allele. Warnings and Precautions (5.1) [see] with prior hypersensitivity reaction to abacaviror lamivudine. Use in Specific Populations (8.7) [see] with moderate or severe he
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
112 trials linked to this intervention
Recent Trials
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
Long-Term Lamivudine Therapy for Chronic Hepatitis B
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
Immunologic Memory (Supp. of ATN 024)
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Lamivudine (substance)
- SNOMED CT
- 386897000
- UMLS CUI
- C0209738
- RxNorm CUI
- 68244
- Labeler
- Laurus Labs Limited
Clinical Data
This intervention maps to 3 entities in the Healos knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.